Best Pairing with 2'-FL
LNnT makes the most sense when the nutrition company wants to build a formula story beyond one fucosylated HMO. It adds neutral core coverage and helps create a more balanced HMO portfolio.
Neutral Core HMO
Lacto-N-neotetraose (LNnT)
Lacto-N-neotetraose gives technical teams a neutral core HMO option with a dry-matter purity specification. Nutrition companies often review LNnT together with 2'-FL when they plan early-life nutrition or multi-HMO product concepts.
Nutrition companies usually compare LNnT purity, residue indicators, application fit, and destination-market requirements before sampling or commercial formulation.
- Neutral core HMO option for 2'-FL blend concepts
- GMP-standard production line and stable supply capacity
- Batch residue testing and internal release standards
Fermentation-Based HMO- Molecular Formula
- C26H45NO21
- Relative Molecular Mass
- 707.63
- HMO Family
- Neutral Core HMO
- Appearance
- White to off-white powder
CAS No.13007-32-4
MOQ10 kg
Shipping PortShanghai or Qingdao
PurityLNnT dry matter, >=92.0%
Application and Regulatory Review
LNnT Application, Use-Level, and Regulatory Review
Review LNnT application direction, use-level references, permitted categories, labelling points, and destination-market requirements before sampling, quotation, or commercial formulation.
Infant Nutrition R&D
Use LNnT for infant formula, follow-on formula, young-child nutrition, and early-life R&D where the target market allows the ingredient and use level.
Gut Microbiota Concepts
We use LNnT in gut microbiota and immune-development discussions, but we keep this wording as application direction rather than a final consumer claim.
FSMP and Hydrolyzed Formula Review
LNnT is useful in special-nutrition review because nutrition companies often need both ingredient identity and target-population justification before choosing a use level.
EU Novel Food Review
EU 2023/961 updates conditions of use for LNnT, and EU 2023/1583 updates specifications for microbial-source LNnT. Nutrition companies should use the product-specific EU entries together with the intended food category and source review.
U.S. GRAS Review
The FDA GRAS Notice Inventory includes LNnT entries with 'no questions' response letters, including GRN 659, GRN 895, GRN 919, GRN 1059, and GRN 1067. GRN 1067 gives a useful current reference for formula, young-child foods, drinks, yogurt, meal replacements, and bars.
Use-Level Review Notes
- FDA GRN 1067 lists LNnT for nonexempt infant formula for term infants up to 0.60 g/L and formula for young children over 12 months up to 0.6 g/L.
- FDA GRN 1067 lists drinks for young children, sports/isotonic/energy drinks, milk and imitation milk, buttermilk, fruit juices, and nectars up to 0.58 g/L.
- FDA GRN 1067 lists foods for infants and young children up to 3.0 g/kg, yogurt up to 2.67 g/kg, meal replacement drinks up to 2.5 g/L, and meal replacement bars up to 20 g/kg.
- EU review anchors include 0.6 g/L for infant formula and 0.6 g/L for follow-on formula in final product ready for use.
- EU food supplement entries include 1.5 g/day for the general population and 0.6 g/day for young children.
- For products with both 2'-FL and LNnT, review combined HMO exposure and same-day-use labelling.
Technical Data
Specification Snapshot
LNnT Specification
| Color | White to off-white |
|---|---|
| Appearance | Powder |
| Lacto-N-neotetraose (Dry Matter) | >=92.0% |
| Lacto-N-neotetraose Fructose Isomer | <=1.0% |
| D-Lactose | <=3.0% |
| Lacto-N-triose II | <=3.0% |
| Lacto-N-neohexaose (LNnH)-linear | <=3.0% |
| Total Sugars (Dry Matter) | >=95.0% |
| Residual Proteins | <=100 mg/kg |
| Endotoxins | <=10 EU/mg |
| Methanol | <=100 mg/kg |
| pH (20 C, 5% Solution) | 4.0-7.0 |
| Water | <=8.0% |
| Ash | <=0.4% |
| Total Arsenic | <=0.1 mg/kg |
| Cadmium | <=0.1 mg/kg |
| Lead | <=0.05 mg/kg |
| Mercury | <=0.01 mg/kg |
| Aflatoxin M1 | <=0.05 ug/kg |
| Aerobic Plate Count | <=500 CFU/g |
| Moulds | <=10 CFU/g |
| Yeasts | <=10 CFU/g |
| Bacillus cereus | <=50 CFU/g |
| Enterobacteriaceae | <10 CFU/g |
| Salmonella | Absent in 25 g |
| Cronobacter spp. | Absent in 100 g |
| Staphylococcus aureus | <10 CFU/g |
| Listeria monocytogenes | Absent in 25 g |
| Exogenous DNA Residues | Negative |
| Genetically Modified Microbial Living Cell Residues | Not Detected |
Specification Notes
- Product Description
- Lacto-N-neotetraose (LNnT) is a neutral core HMO ingredient prepared from lactose-based raw material through fermentation, purification, and drying. It is often reviewed with 2'-FL when a nutrition company builds early-life or multi-HMO concepts.
- Storage Condition
- Store at room temperature in the original sealed package.
- Pack Size and Shelf Life
- 20 kg per carton, packed as 10 kg x 2 bags. Best use before: 24 months.
- Packaging Material
- Inner packaging uses food-grade composite film bags and food-grade composite aluminum foil bags. Outer packaging uses a carton.
- Anticipated Use
- For formulation review in children's milk powder, infant formula, older-infant and young-child formula, and infant formula for special medical purposes, subject to the destination market's authorization.
Project Support
Planning a LNnT or Multi-HMO Project?
Share your specification target, annual forecast, and market requirements. We will help check supply options, sample route, and application direction.